Leukocyte telomere length and renal cell carcinoma survival in two studies

Catherine L. Callahan, Kendra Schwartz, Julie J. Ruterbusch, Brian Shuch, Barry I. Graubard, Qing Lan, Richard Cawthon, Andrea A. Baccarelli, Wong Ho Chow, Nathaniel Rothman, Jonathan N. Hofmann, Mark P. Purdue

Research output: Contribution to journalArticlepeer-review

16 Scopus citations

Abstract

Background:Leukocyte telomere length (LTL) is a potential biomarker of cancer prognosis; however, evidence for renal cell carcinoma (RCC) is inconsistent.Methods:We investigated LTL and RCC-specific survival among 684 cases from the US kidney cancer study (USKC) and 241 cases from the prostate, lung, colorectal, and ovarian cancer screening trial (PLCO). Leukocyte telomere length was measured by quantitative polymerase chain reaction, and hazard ratios (HRs) and 95% confidence intervals (CIs) computed using multivariable Cox models.Results:Short LTL was associated with poorer disease-specific survival in both USKC (lowest vs highest quartile: HR: 2.3, 95% CI: 1.2-4.4; P for trend=0.02) and PLCO (HR: 2.4, 95% CI: 1.0-5.4; P=0.04). Among USKC cases, the association was strongest for stage-I RCC (HR: 5.5, 95% CI: 1.6-19.0; P=0.006).Conclusions:Our findings suggest that shorter LTL is an independent marker of poor RCC prognosis, particularly for stage-I disease.

Original languageEnglish (US)
Pages (from-to)752-755
Number of pages4
JournalBritish journal of cancer
Volume117
Issue number5
DOIs
StatePublished - Aug 22 2017

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Leukocyte telomere length and renal cell carcinoma survival in two studies'. Together they form a unique fingerprint.

Cite this